April 28, 2014
Watson Laboratories Inc. and Mylan Pharmaceuticals Inc. hit the U.S. Food and Drug Administration with separate lawsuits Monday after the regulator determined another generic-drug maker still has exclusivity rights to market its version of Pfizer Inc.'s arthritis drug Celebrex.